August 30, 2016 / 1:12 PM / a year ago

BRIEF-Valeant acquires Canadian rights for Contrave in treatment of obesity

1 Min Read

Aug 30 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant acquires the Canadian rights for Contrave in the treatment of obesity

* Valeant expects to file with health Canada for regulatory approval by January 2017

* Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses

* Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016

* Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below